Searched for
ASTHMA DRUG
These large- and mid-cap stocks can give more than 25% return in 1 year, according to analystsThere are market phases when one risk dominates. Then there are phases like this, when risks arrive from every direction and refuse to stan...- These large- and mid-cap stocks may give more than 25% return in 1 year, according to analystsFor the last few earnings seasons, the message has been: “Show me growth, I have the money.” Stocks with better-than-expected earnings saw ...
- These large- and mid-cap stocks can give more than 20% return in 1 year, according to analystsHas a peace deal been agreed on by the US and Iran? Will the fragile ceasefire hold? No one can answer these questions with any certainty. ...
- Long-term Investing: Ecosystem with an edge called India; 12 large- mid- and small-cap stocks with upside potential of up to 34%Tactical investing should not be confused with long-term investing. In a world where geopolitical risk, commodity shocks, and uncertainty a...
- Fake mango alert: 3,800 kg of chemically made pulp seized in Pune. Know side effects & how to identify artificially ripened aam at homeMango Adulteration Alert: With the mango season in full swing, rising cases of mango adulteration in India have sparked serious food safety...
- Mankind Pharma enters exclusive pact to distribute AstraZeneca's anti-asthma drug Symbicort in IndiaAstraZeneca Pharma India has partnered with Mankind Pharma to exclusively distribute its anti-asthma drug Symbicort in India. AstraZeneca w...
- GSK boosts respiratory portfolio with $1.4 bn Aiolos Bio dealGSK will pay $1 billion upfront and up to $400 million in certain success-based regulatory milestone payments. It will also make milestone ...
- HC restrains Glenmark from selling asthma drug under 'Indamet' nameSun Pharma and Glenmark are contesting over their right to use drug names "Istamet" and "Indamet", respectively, which Sun Pharma finds to ...
- Lupin launches digital asthma educator platformThe new platform is the latest initiative under Lupin's long running umbrella programme, Joint Airways Initiative (JAI), for patients suffe...
- AstraZeneca gets DCGI nod for asthma drugThe company has received approval from the DCGI for Fasenra (Benralizumab solution for injection in a single dose prefilled syringe30 mg/ml...
- AstraZeneca Pharma gets DCGI nod to market asthma drugAstraZeneca Pharma said the receipt of this permission paves way for the launch of Benralizumab (Fasenra) in India, subject to the receipt ...
- Lupin gets USFDA nod for Asthma drugQuoting IQVIA MAT September data, Lupin said, the said Asthma drug had annual sales of around USD 474.5 million in the US.
- Unichem Labs gets USFDA nod for asthma drugThe tablets are indicated for prophylaxis and chronic treatment of asthma in adults and pediatric patients - 12 months of age and older.
- AstraZeneca gets marketing nod for asthma drug SymbicortResults from AstraZeneca's two clinical studies have shown that the addition of formoterol to budesonide improved asthma symptoms and lung ...
- Cipla plea in High Court against change in price of asthma drugsCipla claimed that the price of the powdered form of its three asthma drugs were capped without following the proper procedure prescribed u...
- New treatment for asthma may be just five years awayResearchers described the previously unproven role of the calcium sensing receptor (CaSR) in causing asthma, a disease which affects 300 mi...
- Lupin launches asthma drug delivery device in USThe agreement grants Lupin exclusive rights to promote, distribute and market InspiraChamber VHC in the US, it added.
- Indian pharma companies like Aurobindo and Glenmark set to gain from USFDA nod for asthma drugIndian drug makers are set to benefit from a decision by the USFDA to allow sale of generic Singulair tablets used for treating asthma and ...
- Ranbaxy, DRL asthma pills to get 93 per cent cheaperDrug price regulator National Pharmaceutical Pricing Authority (NPPA) has started deciding the MRP for anti-asthma drug Doxofylline in a mo...
- Pay more for new asthma drugsIn an attempt to thwart price control, drug majors have withdrawn or reduced supplies of popular asthma drug Theophylline.
Load More
